Forgot Password?
Return to Course Listing

CME: Cold agglutinin disease (CAD): Updates from the American Society of Hematology (ASH) 2019 annual meeting

Activity Description / Statement of Need:

In this online, self-learning activity:

Cold agglutinin disease (CAD) is a subtype of autoimmune hemolytic anemia (AIHA) and characterized by cold agglutinin (CA) autoantibodies that cause the erythrocytic hemolysis. Also known as primary or idiopathic CAD, it is distinguished further from cold agglutinin syndrome (CAS), which is a complication of known conditions such as malignancy, infection, or autoimmune disease. Little is known about the epidemiology of CAD; one small study estimated incidence of 1 per 1 million people and prevalence of 1 per 16 million people with females twice as likely males to develop the disease and a median age of onset of 67 years.

This learning activity has been designed to educate and update HCPs’ knowledge of CAD management as well as improve related competence and performance.

Target Audience:

The following healthcare professionals (HCPs): hematologists, oncologists, immunologists; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and any other HCPs with an interest in or who clinically encounter patients with CAD.


Commercial Support Disclosure: This activity is supported by educational grants from Sanofi / Genzyme.

Learners may participate in this activity free of charge.


Release Date: February 21, 2020 -- Expiration Date: February 21, 2022

Faculty: Adrienne Phillips, MD

Agenda

Faculty introduction and disclosures

Introductory content: overview of CAD

  • Epidemiology
  • Pathogenesis
  • Symptoms, clinical presentation

Diagnostic tools and criteria

  • Diagnosis and differential diagnoses
  • Differences in diagnosing different subtypes of AIHA

CAD treatment

  • Non-pharmacologic strategies: cold-avoidance, plasmapheresis, surgical considerations
  • Pharmacologic therapy
    • Goals of therapy
    • Current treatment
    • Emerging therapies
    • Clinical trial evidence
    • Supportive care
    • Patient case(s)

Summary, conclusions, best practice recap

 

Learning Objectives

By the end of the session the participant will be able to:

  • Describe the pathogenesis and symptomology of AIHA generally and CAD specifically
  • Describe how diagnosis of CAD is distinguished from other subtypes of AIHA and challenges to successful identification of patients
  • Describe present and emerging treatment options for CAD and monitoring parameters for effectiveness of treatment
  • Develop a safe and clinically effective treatment plan including non-pharmacologic and pharmacologic therapy for patients with CAD

Accreditation

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Adrianne Phillips, M.D. has no relevent financial disclosures. 

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevent financial disclosures.

Commercial Support Disclosure: This activity is supported by educational grants from Sanofi / Genzyme.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version


Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


Additional Courses That Are Related To This Activity

Congenital Thrombotic Thrombocytopenic Purpura (cTTP): Updates from the American Society of Hematology (ASH) 2019 annual meeting

Treating Oncology Patients During COVID-19

Transthyretin amyloidosis (ATTR) and its complications: Optimizing management strategies

Contemporary approaches to advanced diffuse large B-cell lymphoma (DLBCL)